Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients

Description

This study evaluates endocrine therapy-induced alopecia among postmenopausal and premenopausal female patients with breast cancer. Alopecia is one of the most feared side effects of cancer-directed therapy, causing distress in women starting treatment for breast cancer. While alopecia is a well-known side effect of many chemotherapy drugs, it has also been reported by women undergoing endocrine therapy. Despite the frequent reports of alopecia related to endocrine therapy, hair loss is rarely reported as a side effect of endocrine therapy and the exact characterization of alopecia is not well understood. By having postmenopausal and premenopausal breast cancer patients describe their hair loss symptoms experienced while undergoing endocrine therapy, researchers may be able to better characterize the incidence, timing, duration, and severity of alopecia and whether the different types of endocrine therapy cause more or less trouble in this regard.

Conditions

Breast Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This study evaluates endocrine therapy-induced alopecia among postmenopausal and premenopausal female patients with breast cancer. Alopecia is one of the most feared side effects of cancer-directed therapy, causing distress in women starting treatment for breast cancer. While alopecia is a well-known side effect of many chemotherapy drugs, it has also been reported by women undergoing endocrine therapy. Despite the frequent reports of alopecia related to endocrine therapy, hair loss is rarely reported as a side effect of endocrine therapy and the exact characterization of alopecia is not well understood. By having postmenopausal and premenopausal breast cancer patients describe their hair loss symptoms experienced while undergoing endocrine therapy, researchers may be able to better characterize the incidence, timing, duration, and severity of alopecia and whether the different types of endocrine therapy cause more or less trouble in this regard.

Endocrine Therapy-Induced Alopecia Natural History Evaluation Among Female Breast Cancer Survivors

Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients

Condition
Breast Carcinoma
Intervention / Treatment

-

Contacts and Locations

Albert Lea

Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States, 56007

Baxter

Essentia Health Baxter Clinic, Baxter, Minnesota, United States, 56425

Bemidji

Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States, 56601

Brainerd

Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States, 56401

Deer River

Essentia Health - Deer River Clinic, Deer River, Minnesota, United States, 56636

Detroit Lakes

Essentia Health Saint Mary's - Detroit Lakes Clinic, Detroit Lakes, Minnesota, United States, 56501

Duluth

Essentia Health Cancer Center, Duluth, Minnesota, United States, 55805

Ely

Essentia Health Ely Clinic, Ely, Minnesota, United States, 55731

Fosston

Essentia Health - Fosston, Fosston, Minnesota, United States, 56542

Grand Rapids

Fairview Grand Itasca Clinic & Hospital, Grand Rapids, Minnesota, United States, 55744

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age \>= 18 years
  • * Women with a diagnosis of breast cancer who are being treated with curative intent, with the one exception being women who are receiving CDK4/6 inhibitors (these patients being allowed to have more advanced disease)
  • * Provide informed consent
  • * Ability to complete questionnaire(s) by themselves or with assistance
  • * Filling into one of the 5 groups (understanding that groups will close once they complete their accrual goals of 30 patients)
  • * Willingness to complete questionnaires every 3 months
  • * Ability to complete the first questionnaire within 2 weeks of therapy initiation (for the four arms that are receiving adjuvant hormonal therapy)
  • * For patients starting tamoxifen or an aromatase inhibitor: within 2 weeks of starting tamoxifen or aromatase inhibitor
  • * For patients starting a CDK 4/6 inhibitor: within 2 weeks of starting the CDK 4/6 inhibitor (patients may have started an aromatase inhibitor at any time prior to initiation of CDK 4/6 inhibitor).
  • * Verbal baseline alopecia \>= 2 on an 11 point scale (from none = 0 to severe = 10). The question to use for this item is: Please rate your hair thinning or loss on a scale from 0 to 10, with 0 being no hair loss and 10 being complete hair loss
  • * Planned receipt of chemotherapy or another cancer-directed therapy concurrently (e.g., everolimus, etc.; note that a CDK4/6 inhibitor is allowed within cohort 3)
  • * Prior use of endocrine therapy for breast cancer
  • * Receipt of chemotherapy over the previous 6 months

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Elizabeth Cathcart-Rake, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic in Rochester

Study Record Dates

2025-08-01